Micro Market Research
+1-888-502-0539
US/CAN Toll Free

You are here :   Home     Healthcare     infertility Treatment     General & Plastic Surgery     Intrauterine Contraceptive Devices    
Real Time Market Research & Industry Analysis - MicroMarketMonitor

North American Intrauterine Contraceptive Devices (IUD/IUCD) Market by Type (Hormonal IUCD, Copper IUCD) – Forecast to 2019

  • Report Code: IN 1000
  • Publish Date: Feb 2015
  
Description
Table of Contents
Customer Intelligence
Summary
Inquiry Before Buying Ask for Discount

The North America intrauterine contraceptive devices market has been categorized, on the basis of type, into hormonal IUCD and copper IUCD. The hormonal IUCD segment contributed the larger share of 83.4% in 2014 to the total market value of intrauterine contraceptive devices, followed by the copper IUCD segment with 16.6% market share. On the basis of products, this market has been segmented as Mirena, Skyla, ParaGuard, and Essure. The major countries covered in this report for a comprehensive analysis of the concerned market include the U.S. and Canada.

 

The growth of the intrauterine contraceptive devices market is driven by various factors, such as the rising rate of unplanned pregnancies, effective contraception and minimum side effects of IUCD, implementation of the Affordable Care Act (ACA), higher number of initiatives undertaken by private firms directed towards reducing the expenses related to abortion, and the various technological advancements. For instance, the Colorado Family Planning Initiative has provided more than 30,000 intrauterine devices (IUCDs) or implants at low or no cost to low-income women at 68 family planning clinics across Colorado, since 2009. The decline in births among young women, served by these agencies, accounted for three-quarters of the overall decline in the Colorado teen birth rate. As a result, in July 2014, the organization announced that, the teen birth rate in Colorado dropped by 40% from 2009 to 2013, driven by a Colorado Department of Public Health and Environment initiative that helps low-income women get long-acting reversible contraceptives (LARC), such as intrauterine contraceptive devices. High costs of treatment, threat of causing pelvic inflammatory infection (PID), threat of causing ectopic pregnancy, and high rate of complications during unplanned pregnancy are among the main factors hindering the growth of the IUCD market.

 

The report also provides a detailed competitive landscaping of the major companies operating in this market. Segment and country-specific company shares, news & deals, M&As, and segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this research report. The main companies operating in the North American market are Bayer HealthCare AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Actavis Plc. (Ireland), and Medicines360 (Ireland), among others.



Table Of Contents

 

1 Introduction (Page No. - 8)
    1.1 Objectives Of The Study 
    1.2 Market Segmentation & Coverage 
 

2 Research Methodology (Page No. - 11)
    2.1 Integrated Ecosystem Of Intrauterine Contraceptive Devices Market 
    2.2 Arriving At The Intrauterine Contraceptive Devices Market Size 
           2.2.1 Top-Down Approach
           2.2.2 Bottom-Up Approach
           2.2.3 Macro Indicator-Based Approach
    2.3 Assumptions 
 

3 Executive Summary (Page No. - 16)
 

4 Market Overview (Page No. - 18)
    4.1 Introduction 
    4.2 Market Drivers And Inhibitors 
    4.3 Key Market Dynamics 
 

5 North America Intra-Uterine Contraceptive Devices Market, By Type (Page No. - 26)
    5.1 Introduction 
    5.2 Copper Iud 
    5.3 Hormonal Iud 
    5.4 North America Intra-Uterine Contraceptive Devices Market, 

    5.5 North America Hormonal Iud Market, By Country 
    5.6 North America Copper Iud Market, By Country 
 

6 North America Intra-Uterine Contraceptive Devices Market, By Product (Page No. - 32)
    6.1 Mirena 
           6.1.1 Product Positioning And Promotions Of Mirena
    6.2 Skyla 
           6.2.1 Product Positioning And Promotions Of Skyla
    6.3 Paragard 
           6.3.1 Product Positioning And Promotions Of Paragard
    6.4 Essure 
           6.4.1 Product Positioning And Promotions Of Essure
    6.5 Pipeline Products 
           6.5.1 Levosert
 

7 North America Intra-Uterine Contraceptive Devices Market, (Page No. - 42)

    7.1 Introduction 
    7.2 U.S. Intra-Uterine Contraceptive Devices Market 
           7.2.1 U.S. Intra-Uterine Contraceptive Devices (Iucd) Market, By Type
           7.2.2 U.S. Intra-Uterine Contraceptive Devices Market, By Type
    7.3 Canada Intra-Uterine Contraceptice Devices Market 
           7.3.1 Canada Intra-Uterine Contraceptive Devices Market, By Type
 

8 North America Intra-Uterine Contraceptive Devices Market: (Page No. - 51)

    8.1 U.S. Intra-Uterine Contraceptive Devices Market: Company Share Analysis 
    8.2 Canada Intra-Uterine Contraceptive Devices Market: Company Share Analysis 
    8.3 Mergers & Acquisitions 
    8.4 Regulatory Approvals 
    8.5 Partnership 
    8.6 Collaboration 
 

9 North America Intra-Uterine Contraceptive Devices Market, By Company (Page No. - 55)
    9.1 Bayer Healthcare Ag (Subsidiary Of Bayer Ag) 
    9.2 Teva Pharmaceutical Industries Ltd. 
    9.3 Actavis Plc 
    9.4 Medicines360 
    9.5 Trimedic Supply Network Ltd. 
    9.6 Medisafe Distribution Inc. 
    9.7 Pace Pharmaceuticals, Inc. 
 

10 Appendix (Page No. - 68)
     10.1 Related Reports 
     10.2 Introducing Rt: Real Time Market Intelligence 
             10.2.1 Rt Snapshots


List Of Tables 

 

Table 1 North America Intra-Uterine Contraceptive Devices Market: Macro Indicators, By Country, 2013 (Abortion Per 1000 Women Ages 15-44)
Table 2 North America Intra-Uterine Contraceptive Devices Market: Drivers And Inhibitors
Table 3 Global Intra-Uterine Contraceptive Devices Market: Comparision With Global Female Contraceptives Market, 2013–2019 (Usd Mn)
Table 4 North America Intra-Uterine Contraceptive Devices Market, By Country,2013–2019 (Usd Mn) 
Table 5 North America Intra-Uterine Contraceptive Devices Market, By Typ,2013–2019 (Usd Mn) 
Table 6 North America Intra-Uterine Contraceptive Devices Market, By Type,2013–2019 (Usd Mn) 
Table 7 North America Intra-Uterine Contraceptive Devices Market: Type Comparison With Female Contraceptives Market, 2013–2019 (Usd Mn)
Table 8 North America Hormonal Iud Market, By Country, 2013–2019 (Usd Mn)
Table 9 North America Copper Iud Market, By Country, 2012 - 2018 (Usd Mn)
Table 10 North America Intra-Uterine Contraceptive Devices Market, Bycountry, 2012 - 2018 (Usd Mn)
Table 11 North America Intra-Uterine Contraceptive Devices Market, By Type,2012 - 2018 (Usd Mn) 
Table 12 U.S. Intra-Uterine Contraceptive Devices Market, By Type,2013-2019 (Usd Mn) 
Table 13 Canada Intra-Uterine Contraceptive Devices Market, By Type,2012 - 2018 (Usd Mn) 
Table 14 U.S. Intra-Uterine Contraceptive Devices Market: Company Share Analysis, 2013 (%)
Table 15 Canada Intra-Uterine Contraceptive Devices Market: Company Share Analysis, 2013 (%)
Table 16 North America Intra-Uterine Contraceptive Devices Market: Mergers & Acquisitions
Table 17 North America Intra-Uterine Contraceptive Devices Market: Regulatory Approvals
Table 18 North America Intra-Uterine Contraceptive Devices Market: Partnership
Table 19 North America Intra-Uterine Contraceptive Devices Market: Collaboration
Table 20 Bayer Healthcare Ag.: Key Financials, 2008 - 2013 (Usd Mn)
Table 21 Teva Pharmaceutical Industries Ltd.: Key Financials, 2008 - 2013 (Usd Mn)
Table 22 Actavis Plc: Key Financials, 2008 - 2013 (Usd Mn)

List Of Figures 

Figure 1 Evolution Of Iucd
Figure 2 Widely Used Contraceptive Methods
Figure 3 North America Intra-Uterine Contraceptive Devices Market: Segmentation & Coverage
Figure 4 Intrauterine Contraceptive Devices Market: Integrated Ecosystem
Figure 5 Top-Down Approach
Figure 6 Bottom-Up Approach
Figure 7 Macro Indicator-Based Approach
Figure 8 North America Intra-Uterine Contraceptive Devices Market Snapshot
Figure 9 Birth Control Methods Covered Under Affordable Care Act (Aca)
Figure 10 Global Intrauterine Contraceptive Devices Market: Comparison With Global Female Contraceptives Market
Figure 11 North America Intrauterine Contraceptive Devices, By Country,2013 (Usd Mn) 
Figure 12 North America Intrauterine Contraceptive Devices Market, By Type,2013 (Usd Mn) 
Figure 13 Advantages And Disadvantages Of Copper Iucd
Figure 14 Advantages And Disadvantages Of Hormonal Iucd
Figure 15 North America Intra-Uterine Contraceptive Devices Market, By Type,2012 - 2018 (Usd Mn) 
Figure 16 North America Intra-Uterine Contraceptive Devices Market: Type Comparison With Female Contraceptives Market, 2013–2019 (Usd Mn)
Figure 17 North America Hormonal Iud Market, By Country, 2013–2019 (Usd Mn)
Figure 18 North America Copper Iud Market, By Country, 2013–2019 (Usd Mn)
Figure 19 Sales (Usd Million) Of Mirena, U.S., 2012
Figure 20 Adverse Effects Caused By Mirena, U.S., 1997-2012
Figure 21 Product Comparison Between Mirena And Skyla, U.S.
Figure 22 Product Specifications, Levosert
Figure 23 Average Selling Price (Usd) Of Marketed Intra-Uterine Contraceptive Devices (Iucd) In U.S. And Canada, 2013
Figure 24 U.S. Intra-Uterine Contraceptive Devices Market Overview,2014 & 2019 (Usd Mn) 
Figure 25 U.S. Intra-Uterine Contraceptive Devices Market, By Type 2013-2019 (Usd Mn)
Figure 26 Percentage Usage Of Various Contraceptive Devices , U.S., 2010
Figure 27 Percentage Usage Of Various Contraceptive Devices , U.S., 2013
Figure 28 Canada Intra-Uterine Contraceptive Devices Market Overview,2013 & 2018 (%) 
Figure 29 Canada Intra-Uterine Contraceptive Devices Market, By Type,2012-2018 (Usd Mn) 
Figure 30 U.S. Intra-Uterine Contraceptive Devices Market: Company Share Analysis, 2013 (%)
Figure 31 Canada Intra-Uterine Contraceptive Devices Market: Company Share Analysis, 2013 (%)
Figure 32 Bayer Healthcare Ag: Revenue Mix (2013) (%)
Figure 33 Contribution Of Pharmaceuticals Segment Towards Company Revenues, 2008-2013 (Usd Mn)
Figure 34 Teva Pharmaveutical Industries Ltd.: Revenue Mix (2013) (%)
Figure 35 Contribution Of Speciality Medicine Segment Towards Company Revenues, 2008-2013 (Usd Mn)
Figure 36 Actavis Plc: Revenue Mix (2013) (%)

Intra-uterine contraceptive devices are most commonly known as IUD/IUCD. These devices are inserted into the uterus to prevent pregnancy. The IUCD can be a coil, loop, triangle, or T in shape made of plastic or metal. There are many types of IUCDs based on their shapes and sizes. They are usually made up of polypropylene saturated with barium sulfate, to visualize them on x-rays. The commonly used device is ’T’ shaped with a horizontal and vertical arm. The vertical arm has a copper wire wrapped around it and two colored nylon threads at the lower end. This thread (tail), which protrudes through the cervix into the vagina, enables the user to verify its correct placement. An IUCD is 98.0% to over 99.0% reliable in preventing pregnancy. The newer devices, such as Multi Loads ML-Cu-250, ML-Cu-375, and Cu 7 – 380 A, are highly effective, that is greater than 99.0% in birth control assurance.

 

An IUCD is inserted into the uterus by a healthcare professional. IUCD prevents sperms and egg from meeting by either immobilizing the sperms on their way to the fallopian tubes or by changing the uterine lining, so that the fertilized egg cannot implant in it.

 

There are two types of IUCDs approved in the U.S., namely copper and hormonal IUCD. The hormonal IUCDs are of two types. The first is Progesterone IUCD (Progestasert), in which the vertical shaft of the IUCD is fitted with a capsule containing hormone progesterone, which is released in at a steady pace, giving the desired contraceptive effect. The life span of this type of IUCD is around 1 year. The other type is Levonorgestrel IUCD 20 (LNG 20, Lernova), in which the hormone, levonorgestrel is released. The life span for this device is between five and seven years.

 

The North American intra-uterine contraceptive devices market was valued at $778.2 million in 2014, which is expected to reach a value of $789.8 million by 2019, at a CAGR of 0.3% from 2014 to 2019.

 

The hormonal IUCD market contributed maximum high share of 83.4% in 2013 to the total North American intra-uterine contraceptive devices market, followed by copper IUCD with a share of 16.6%. The hormonal IUCD market is expected to reach a value of $659.5 million by 2019, at a CAGR of 0.3% from 2014 to 2019, and the copper IUCD market is expected to reach at $130.3 million by 2019 at a CAGR of 0.2% during the forecast period.

 

Geographically, the U.S. contributed the maximum market share of around 93.0% in 2013 to the North American intra-uterine contraceptive devices market. This market was valued at $724.1 million in 2014, which is expected to reach a value of $734.4 million by 2019, at a CAGR of 0.3% from 2014 to 2019. In terms of growth potential, the Canadian market is an open market, and expected to witness maximum growth in the IUCD market during the forecast period. The Canadian intra-uterine contraceptive devices IUCD market was valued at $54.1 million in 2014, and is expected to reach a value of $55.4 million by 2019, at a CAGR of 0.5% from 2014 to 2019.

 

The key players in the intra-uterine contraceptive devices market are Bayer HealthCare AG (A subsidiary of BAYER AG) (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Actavis plc (Ireland), and Medicines360 (Ireland).

Custom Market Research Services
We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
Connect With Us
US/CAN : +1-888-502-0539